-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, CG Oncology announced that it has reached a clinical trial cooperation agreement with Roche
Oncolytic virus is a type of virus that can selectively lyse cancer cells.
CG0070 is based on a modified adenovirus type 5 (Ad5) backbone, including a tumor-specific promoter, and a granulocyte-macrophage colony stimulating factor (GM-CSF) transgene
▲The pipeline of CG Oncology's products under development (picture source: CG Oncology's official website)
This phase 1/2 clinical trial will test the efficacy and safety of CG0070 in combination with atelizumab in patients with a variety of advanced solid tumors
Mr.
Reference materials:
[1] CG Oncology and Roche to Collaborate on Clinical Trial of Oncolytic Immunotherapy CG0070 as Part of Novel Combination for Various Solid Tumor Indications.